Cosentyx is a biologic drug used to treat psoriasis. According to drugpatentwatch.com [1], the drug's active ingredient is secukinumab, which works by targeting and blocking a specific protein in the body that is responsible for inflammation. The website also notes that Cosentyx was approved by the FDA in 2015 for the treatment of moderate to severe plaque psoriasis in adults.

A study published in the Journal of the European Academy of Dermatology and Venereology [2] evaluated the safety and efficacy of Cosentyx in elderly patients with moderate to severe psoriasis. The study found that Cosentyx was effective in improving psoriasis symptoms in elderly patients, with a high percentage of patients achieving clear or almost clear skin after 12 weeks of treatment. The study also found that Cosentyx was well-tolerated by elderly patients, with no significant safety concerns.

Another study published in Acta Dermato-Venereologica [3] evaluated the long-term safety and efficacy of Cosentyx in patients with moderate to severe psoriasis, including elderly patients. The study found that Cosentyx was effective in improving psoriasis symptoms in elderly patients, with a high percentage of patients achieving clear or almost clear skin after 52 weeks of treatment. The study also found that Cosentyx was generally well-tolerated by elderly patients, with no significant safety concerns.

In conclusion, based on the studies cited, Cosentyx appears to be an effective and safe treatment option for elderly patients with moderate to severe psoriasis. However, it is important to note that individual results may vary, and patients should consult with their healthcare provider to determine if Cosentyx is the right treatment option for them.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://pubmed.ncbi.nlm.nih.gov/29404966/
[3] https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3678.